NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company’s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company’s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

Research Grants show all


Publications show all

Northwest Biotherapeutics has published 32 articles.

Patents show all


Clinical Trials show all

2Phase 1/Phase 22Phase 31N/A1Phase 11Phase 2

SEC Filings show all


Contact Information

4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
United States



    Total FundingEmployeesLast Funding DateStatus

    Crunchbase Investment Rounds

    DateAmountRoundValuationLead InvestorOther Investors
    2017-12-06$12,000,000Post Ipo Equity
    2015-04-03$40,000,000Post Ipo EquityWoodford Investment Management
    2013-11-26$27,000,000Post Ipo Equity
    2014-11-20$35,000,000Post Ipo EquityWoodford Investment Management
    2010-12-09$395,000Series Unknown
    2016-03-15$10,000,000Post Ipo Debt
    2014-10-07$11,500,000Post Ipo Equity

    SEC Form D Funding Events

    2010-12-09$395,000$395,000Equity, Debt, Option to Acquire
    2006-04-17UnknownUnknownOther (Paper Filing)

    Key Executives

    • Alton L. Boynton
      Executive Officer
    • Linda F. Powers
    • Robert Farmer